Accreditation
This activity is intended for pediatric, general, and geriatric psychiatrists, nurse practitioners, physician assistants, nurses, and other mental health professionals engaged in the care of patients with psychiatric and mood disorders.
As a result of participating in this activity, participants should be better able to:
- Assess the physiologic function of novel receptors in the brain and their role as potential therapeutic targets.
- Demonstrate greater confidence related to understanding the Modes of Action of emerging treatments for Schizophrenia, Bipolar Disorder, Mood, and Psychotic Disorders.
- Compare clinical data on the efficacy and safety of emerging psychotropic agents across psychiatric conditions.
- Recognize where novel psychotropic agents may fit into the treatment paradigm for patients with Schizophrenia and Bipolar Disorder, Mood, and Psychotic Disorders.
- Assess the efficacy and safety of current pharmacotherapies for delirium and dementia, including medication combinations and adjunctive therapies.
- Recognize the risk of treatment non-response and relapse in patients with Schizophrenia, Bipolar Disorder, Mood, and Psychotic Disorders.
- Discuss current definitions, criteria, and recent guidelines for treatment resistance in various psychiatric disorders.
- Evaluate therapeutic options for patients who have an inadequate response to treatment, including the use of combination and augmentation therapies.
- Develop individualized treatment plans for neuropsychiatric disorders using personalized medicine strategies.
- Incorporate novel approaches to the clinical management of complex psychiatric disorders.
- Review factors that impact the emergence of adverse effects of psychotropic drugs.
- Evaluate strategies to monitor for and manage adverse effects to improve patient adherence and optimize clinical outcomes.
- Increase knowledge of pathophysiologic basis of agitation associated with Alzheimer’s disease.
- Increase knowledge of the mechanism of action of pharmacotherapies studied for the management of agitation associated with Alzheimer’s disease.
- Recognize where emerging therapies with novel MOAs may fit into future treatment strategies for adult and pediatric populations living with ADHD.
- Increase knowledge with the latest clinical data and emerging ADHD treatments for both adult and pediatric populations.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Global Academy for Medical Education. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
The University of Cincinnati designates this Live Activity for a maximum of 13.25 AMA PRA Category 1 Credits™.
ABPN Diplomates may select any CME activity relevant to their practice to count towards ABPN MOC requirements.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Global Academy for Medical Education. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The maximum number of hours awarded for this Continuing Nursing Education activity is 13.25 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses will be determined and indicated on your certificate.
Postgraduate Institute for Medicine designates this continuing education activity for 13.25 contact hours (1.35 CEUs) of the Accreditation Council for Pharmacy Education.
The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
